Effect of Dapagliflozin combined with Entresto in the treatment of heart failure after emergency interventional therapy in non-diabetic acute myocardial infarction patients

Su Peng; Yang Xiuli

doi:10.3969/j.issn.1674-4055.2023.08.17

Abstract：Objective To investigate the effect of Dapagliflozin combined with Entresto in treating heart failure after emergency interventional therapy in non-diabetic acute myocardial infarction patients.Methods A total of 100 cases of non-diabetic acute myocardial infarction patients treated in the Third Affiliated Hospital of Xinxiang Medical College from June 2021 to June 2022 after emergency interventional treatment of heart failure were selected as the study objects.Moreover,the patients were randomly divided into a control group(Entresto)and an observation group(control group combined with Dapagliflozin)with 50 cases each.After one week of treatment,24 h urine volume,uric acid(UA),hypersensitive C-reactive protein(hs-CRP),and N-terminal B-type natriuretic peptide(NT-proBNP)were observed in both groups before and after treatment.After three months of treatment,left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),6-min walking distance(6MWD),and major cardiovascular adverse events(MACE)and adverse reactions during follow-up were recorded.Results After one week of treatment,NT-proBNP,hs-CRP,and UA in both groups were lower than before treatment(P<0.05)and decreased in the observation group(P<0.05),24-hour urine volume levels were higher than before treatment(P<0.05),and increased in the observation group(P<0.05);After three months of treatment,LVESD and LVEDD were decreased in both groups compared with before treatment(P<0.05)and decreased in the observation group(P<0.05),LVEF and 6MWD levels were increased compared with before treatment(P<0.05),and increased in the observation group(P<0.05),and the incidence of MACE was lower in the observation group.The difference was statistically significant(P<0.05).There was no significant difference in the adverse reaction rate between the two groups(P>0.05).Conclusion The efficacy of Dapagliflozin combined with Entresto in the treatment of heart failure after emergency interventional therapy in non-diabetic patients with acute myocardial infarction is better than that of Entresto alone,which can improve cardiac function and ventricular remodeling,reduce the incidence of MACE,and has good safety.